The company has not filed an annual or quarterly report since its FY2017 10-K, filed Mar 8, 2018. Its latest SEC filing is a CT ORDER from Apr 11, 2019.
10-K for FY2017, filed Mar 8, 2018
The sections below describe the company as of the FY2017 annual report.
Develops cancer drug candidates, including tucatinib for metastatic breast cancer, for cancer patients.
10-K for FY2017, filed Mar 8, 2018
No revenue was reported.
10-K for FY2017, filed Mar 8, 2018
8-K, filed Mar 9, 2018
As described in the Introductory Note above, on March 9, 2018, Merger Sub irrevocably accepted for payment all Shares that were validly…View ↗
Development focus
The older report included a cancer vaccine among its clinical candidates and described protocell technology for cancer and rare-disease programs; the later report centers development on tucatinib and other preclinical programs.
10-K for FY2014, filed Mar 10, 2015 10-K for FY2017, filed Mar 8, 2018We are a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer.…View ↗
We are conducting a Phase 1 trial for ONT-10, a cancer vaccine directed against the MUC1. Results from this trial have demonstrated that…View ↗
We are increasingly focused on expanding our pipeline of product candidates through both internal research and collaborative efforts. To…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Our goal…View ↗
Although our efforts are focused primarily on developing and commercializing tucatinib, we have two preclinical programs. Our earlier stage…View ↗
Our StrategyView ↗
Research approach
The older report described internal discovery research and expanded research capability; the later report says it closed internal laboratory operations and sought partners for earlier-stage programs while focusing on tucatinib.
10-K for FY2014, filed Mar 10, 2015 10-K for FY2017, filed Mar 8, 2018Increase our product pipeline through discovery research and preclinical development. We seek to develop new product candidates through…View ↗
In November 2017, we decided to pursue partnering opportunities for CASC-578, a Chk1 kinase inhibitor, and CASC-674, a TIGIT antibody…View ↗
Competes with Roche/Genentech, GlaxoSmithKline, and Puma Biotechnology
10-K for FY2017, filed Mar 8, 2018Tucatinib. Tucatinib is an inhibitor of the receptor tyrosine kinase HER2, also known as ErbB2. Multiple marketed products target HER2…View ↗
Loading...
